Carbon Monoxide Levels and Sickle Cell Disease Severity

This study is currently recruiting participants.
Verified December 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01547793
First received: March 6, 2012
Last updated: March 14, 2014
Last verified: December 2013
  Purpose

Background:

- Some people with sickle cell disease have different health problems than others. This may be related to how easily and frequently the red blood cells break apart in the blood. Researchers want to test breath and blood samples from people with sickle cell disease to look for very small amounts of carbon monoxide, which is produced when red blood cells break apart. They will compare these results with breath samples from healthy volunteers. Studying different levels of carbon monoxide may help predict what health problems a person with sickle cell disease may get. It may also provide more information on possible treatments.

Objectives:

- To study breath carbon monoxide levels and their possible relation to the severity of sickle cell disease.

Eligibility:

  • Individuals at least 18 years of age with sickle cell disease.
  • Healthy volunteers who are matched for age, sex, and race with the sickle cell disease group.

Design:

  • Participants will be screened with a medical history.
  • Participants with sickle cell disease will provide a blood sample and have a heart function test. They will also breathe into a bag to provide an exhaled breath sample.
  • Healthy volunteers will provide an exhaled breath sample.
  • No treatment or care will be provided as part of this study.

Condition
Sickle Cell Disease
Sickle Cell Anemia
Anemia, Sickle Cell

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 150
Study Start Date: January 2012
Detailed Description:

Sickle cell disease is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Approximately 0.15% of African-Americans are homozygous for sickle cell disease, and 8% have sickle cell trait. Hemoglobin S polymerization leads to red cell rigidity, microvascular obstruction, inflammation, and end-organ ischemic injury. Our published data indicate that up to 50% of sickle cell patients have vascular dysfunction due to impaired bioavailability of endogenous nitric oxide, due in large part to scavenging of nitric oxide by cell-free hemoglobin. In previous studies we have demonstrated that steady-state serum LDH is strongly associated with 1) other markers of intravascular hemolysis including plasma cell-free hemoglobin and arginase levels, 2) levels of soluble endothelial adhesion molecules, and 3) an impaired vasodilatory response to an NO donor. Further, significant steady-state LDH elevation identified a subset of patients in our cohort as well as the CSSCD cohort at increased risk for developing pulmonary hypertension, cutaneous leg ulceration, priapism, and early death. Previous biochemical studies have demonstrated significant transient increases in serum LDH and plasma hemoglobin levels during VOC, and this presumed hyperhemolysis has been confirmed by 51Cr labeled RBC studies that revealed further decreases in RBC survival during VOC. However, serum LDH levels are not a specific biomarker of hemolysis, and furthermore these observations on RBC survival have not been correlated with markers of intravascular hemolysis at baseline in patients with sickle cell disease in order to confirm the presence of chronic hyperhemolysis subphenotypes in sickle cell disease as posited in our previous work.

The current gold standards of random and cohort labeling of RBCs used to quantitate RBC survival suffer from many technical drawbacks that make them impractical for routine clinical use. The production rate of expired CO has previously been used to assess RBC survival, based upon the principal that virtually all CO produced in human beings results from cleavage of the ?-methene bond of heme and is completely excreted via the lungs. Because RBC destruction accounts for approximately 80% of heme turnover in the body, endogenous CO production can be used as a quantitative indicator of RBC life span. Furne et al have previously reported on the development of a simple, rapid, and noninvasive method for determining RBC life span based on measurement of exhaled alveolar CO concentration immediately upon awakening corrected for atmospheric CO, as determined with a device that simulates the body s equilibration with CO with results comparable to standard labeling techniques. We propose that this methodology could also provide a quantitative, simple, and noninvasive test to study the RBC life span and thus rate of hemolysis in those patients with sickle cell disease.

This trial will aim to 1) establish the use of end-alveolar CO concentration as a quantitative measure of RBC life span and hemolytic rate in subjects with sickle cell disease; 2) investigate the association between end-alveolar CO concentration-derived RBC life span and laboratory measures of hemolytic severity; and 3) investigate the association between end-alveolar CO concentration-derived RBC life span and the incidence of various clinical sequelae of sickle cell disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • ELIGIBILITY CRITERIA:

All volunteer subjects must be at least 18 years of age and have provided informed, written consent for participation in this study. Eligibility in the study is determined prior to enrollment on the basis of the following inclusion and exclusion criteria. Laboratory values obtained within the preceding 60 days are sufficient for screening purposes.

INCLUSION CRITERIA for SCD Cohort

Males or females 18 years of age or older

Diagnosis of sickle cell disease (any form; electrophoretic or HPLC documentation is required)

EXCLUSION CRITERIA for SCD Cohort

Chronic scheduled transfusions

Current known pregnancy or lactation

Hemoglobin < 5.0 g/dL; however, subjects may return for repeat evaluation at a later date

Currently smoking and unable to refrain from smoking for 24 hours

Subjects previously known to have conditions that may independently affect hemolytic rate:

  • Infection or sepsis in the 2 weeks prior to screening
  • Autoimmune hemolytic anemia
  • Systemic lupus erythematosus (SLE)
  • Myelodysplastic disorders, leukemia, or lymphoma
  • Hereditary spherocytosis or elliptocytosis
  • Severe cardiac valve dysfunction (e.g. AS, MS) or prosthetic heart valve recipients

INCLUSION CRITERIA for Controls

In order to validate the methodology for endogenous CO measurement, initially for each enrolled study subject with sickle cell disease (up to the first 30 subjects), we will recruit an African-American healthy control subject of the same gender, within 3 years of age older or younger than the matched subject with SCD. Additionally, 20 healthy control subjects will be enrolled for adenosine and any functionally or chemically related molecules blood testing, and venous blood gas testing only, to compare against subjects with sickle cell disease. Their participation in this study will consist of one blood draw of 11 mL for research laboratory testing.

EXCLUSION CRITERIA for Controls

Current pregnancy or lactation

Serum ALT values > 80 IU/L

Serum creatinine > 2.0 mg/dL

Hemoglobin < 11.2 g/dL for females, < 13.7 for males; however, subjects may return for repeat evaluation at a later date

Currently smoking

Subjects with any known form of sickle cell disease (sickle trait will NOT be excluded)

Subjects with any other known forms of hemolytic anemia

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01547793

Contacts
Contact: Mary J Jackson, R.N. (301) 827-4558 jacksonmj@l.nih.gov
Contact: Caterina P Minniti, M.D. (301) 594-3455 minnitic@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: Caterina P Minniti, M.D. National Heart, Lung, and Blood Institute (NHLBI)
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT01547793     History of Changes
Other Study ID Numbers: 120069, 12-H-0069
Study First Received: March 6, 2012
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Hemolytic Severity
Erythrocyte
Sickle Cell Disease
SD

Additional relevant MeSH terms:
Anemia
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Carbon Monoxide
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014